The immunohistochemistry market is projected to reach USD 2.12 billion by 2021, growing at a CAGR of 7.3% during the forecast period. Rising geriatric population, growing prevalence of chronic diseases, rapid technological developments in the IVD industry, and increasing healthcare spending are expected to fuel the growth of this market in the coming years. However, rapid growth in the developing countries across APAC and Latin America and the increasing demand for personalized medicine are expected to offer significant growth opportunities for players in the market. Regulatory restrictions in developed countries, however, are a major challenge faced by market players in the current immunohistochemistry market.
Based on products, the market is segmented into antibodies, reagents, kits, and equipment. In 2015, the antibodies segment accounted for the largest share of the global immunohistochemistry market. The rising adoption of high-throughput assays, such as array comparative genomic hybridization, cDNA microarray, next-generation sequencing techniques, and histological tests, have led to the rapid discovery of thousands of potential antibodies
Immunohistochemistry market is categorized into two application segments, namely, diagnostics and drug testing. The global market for diagnostic applications is further segmented into infectious diseases, cancer, cardiovascular diseases, diabetes, autoimmune diseases, and nephrological diseases. In 2015, the diagnostics segment accounted for the largest share of the global market. The large share of this segment is attributed to growing prevalence of cancer, and wide application of immunohistochemistry in the diagnosis of cancers, infectious diseases, cardiovascular diseases, and other diseases.
North America dominates the global market, and this trend is expected to continue during the forecast period. The large share of North America can be attributed to the fact that the majority of big players operating in the market are located in this region. In addition, the increasing geriatric population and rising incidence of chronic diseases like cancer, infectious diseases, and cardiovascular disease in this region are expected to boost the market for diagnostics.
F. Hoffman-La Roche AG commanded a share of 22.1% of the global immunohistochemistry market in 2015. The company is a leading immunohistochemistry product manufacturer and supplies its products to hospitals, research laboratories, pharmaceutical companies, and contract research organizations. Roche mainly focuses on acquisitions as its key business strategy. In line with this strategy, in August 2015, Roche acquired GeneWEAVE BioSciences, Inc. (U.S.), a privately held company focused on innovative clinical microbiology diagnostics solutions. Furthermore, in December 2014, the company acquired GeneWEAVE BioSciences, Inc. (U.S.), a privately held company focused on innovative clinical microbiology diagnostics solutions, and Ariosa Diagnostics, Inc. (U.S.), a molecular diagnostics testing service provider that provides a highly targeted and accurate non-invasive prenatal testing (NIPT) service through its CLIA laboratory using cell-free DNA (cfDNA) technology. This acquisition strengthened Roche’s immunohistochemistry and tissue diagnostic business. Roche Diagnostics also focuses on expanding its business globally in order to strengthen its position in the immunohistochemistry market. The company aims to expand its business in high-growth regions such as the Middle East and Africa, Asia-Pacific, and Latin America. Currently, the geographic segments of Europe and North America account for about 68% of the company’s diagnostics business. Furthermore, the company has a strong product portfolio for immunohistochemistry, which comprises antibodies, detection systems, blockers, antibodies diluents, and other ancillaries.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
